A comprehensive review of enhanced bioavailability, nutraceutical efficacy, and superior manufacturing quality of Liposomal Curcumin by WBCIL

1. Introduction

Curcumin, the principal bioactive component of Curcuma longa (turmeric), has garnered significant scientific interest due to its potent anti-inflammatory, antioxidant, and anticancer properties.[1] Despite its promising therapeutic potential, clinical application of curcumin has been severely limited by its poor water solubility, instability in physiological conditions, and rapid systemic elimination, resulting in extremely low oral bioavailability.[1] Conventional curcumin formulations often fail to achieve therapeutically relevant plasma concentrations, thereby limiting their efficacy in both clinical and supplementary contexts.[1]

To overcome these pharmacokinetic challenges, liposomal encapsulation has emerged as a highly effective delivery system.[2] Liposomes, composed of phospholipid bilayers, enhance the solubility, stability, and cellular uptake of curcumin, allowing for improved absorption and bioavailability.[2] In this comprehensive review, we aim to critically examine the absorption profiles of non-liposomal versus Liposomal Curcumin, shedding light on the significant advantages offered by liposomal formulations in diverse application areas. Particular emphasis will be placed on dietary supplementation and topical applications, where bioavailability plays a pivotal role in therapeutic efficacy.

This article will also explore an array of peer-reviewed clinical studies that directly compare the pharmacokinetics and therapeutic outcomes of liposomal and non-liposomal Curcumin. Through a careful synthesis of empirical evidence, we aim to provide a robust scientific foundation for understanding the superiority of Liposomal Curcumin. These clinical insights will be instrumental in shaping future research directions and optimizing formulation strategies.

In addition to reviewing existing literature, the article will spotlight the unique formulation technologies developed by West Bengal Chemical Industries Ltd., Kolkata, India (WBCIL). Our proprietary methodologies, including advanced spray-drying techniques and strict adherence to ISO and GMP-certified production protocols, ensure high-quality Liposomal Curcumin products with minimal microbiological load. These quality parameters underscore the safety, stability, and efficacy of our formulations and reinforce our commitment to innovation in drug delivery science.

By offering a structured and insightful analysis of Liposomal Curcumin, this review serves as both a scientific resource and a foundational platform for future investigations and product developments in this domain.

2. Literature Review

2.1. Limitations of Conventional Curcumin and the superiority of liposomal delivery system

Nutraceutical value of curcumin in inflammation, cancer, neurodegeneration, and metabolic disorders is well established in the literature. However, its supplemental translation has been significantly hampered by its poor pharmacokinetic profile.[3] After oral ingestion, curcumin undergoes extensive first-pass metabolism and is rapidly converted into water-soluble but pharmacologically less active conjugates, such as curcumin glucuronides and sulfates [3]. As a result, even doses as high as 12 g/day result in extremely low plasma concentrations, limiting its systemic therapeutic effectiveness [4]. To address these challenges, liposomal delivery systems have emerged as an advanced platform for improving the absorption and systemic availability of curcumin. Liposomes encapsulate curcumin within lipid bilayers, enhancing its solubility and protecting it from premature degradation in the gastrointestinal tract. This structural design enables a more sustained and controlled release profile, along with improved membrane permeability and cellular uptake [5,6]. Comparative pharmacokinetic studies have demonstrated that Liposomal Curcumin exhibits 5–10 times greater bioavailability than standard curcumin formulations in preclinical and clinical settings [7,8]. These enhancements result from the ability of liposomes to bypass enzymatic barriers and facilitate endocytotic absorption mechanisms in intestinal epithelial cells. Such advancements not only make curcumin more supplementally relevant at lower doses but also reduce the incidence of gastrointestinal irritation often associated with high-dose non-Liposomal Curcumin supplements. Consequently, Liposomal Curcumin offers a scientifically validated solution to one of the most persistent challenges in nutraceutical and pharmaceutical applications of this polyphenolic compound.

2.2. Liposomal Drug Delivery as a Novel Approach

Liposomal technology has gained momentum in recent years as a preferred system for drug delivery, especially for hydrophobic compounds such as curcumin. Liposomes are microscopic spherical vesicles composed of natural or synthetic phospholipids that mimic the structure of cell membranes. Their amphiphilic nature allows for the incorporation of both water-soluble and lipid-soluble drugs, enhancing stability, solubility, and absorption across biological barriers [9]. In the context of curcumin, liposomal encapsulation has been shown to improve retention time in systemic circulation, protect the active ingredient from metabolic enzymes, and enable targeted delivery to affected tissues.[10] This technology holds particular promise in clinical conditions where sustained therapeutic exposure is required. Moreover, liposomes can be engineered for site-specific delivery by modifying their surface with ligands or antibodies, which is especially useful in cancer and inflammatory disease management.[10] Thus, liposomal encapsulation represents more than just a method for boosting bioavailability of curcumin—it provides a versatile and customizable platform for enhancing the clinical efficacy of natural compounds.

Topical Use (up arrow represents up-regulation and down arrow represents down regulation)

Liposomal Curcumin has become increasingly recognized for its versatility across both systemic and localized therapeutic applications. As a dietary supplement, it is widely used in the management of chronic inflammation, oxidative stress-related disorders, metabolic syndrome, and neurological conditions. The improved bioavailability of liposomal formulations allows for lower dosing while achieving clinically meaningful effects, which is especially advantageous for long-term use in preventative healthcare. A growing body of clinical evidence supports the efficacy of Liposomal Curcumin in reducing systemic inflammation. A randomized, double-blind, placebo-controlled trial investigated the effects of curcumin supplementation in patients with metabolic syndrome and found significant reductions in inflammatory biomarkers, including C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6), in patients receiving curcumin in a lipid-based form.[11] These anti-inflammatory effects have further implications in managing comorbidities such as insulin resistance, cardiovascular risk, and obesity—all of which are tightly linked to chronic inflammation. Liposomal Curcumin has also demonstrated neuroprotective benefits in several experimental and clinical settings. By crossing the blood-brain barrier more effectively than conventional curcumin, liposomal formulations show promise in neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. Studies have reported improvements in cognitive markers, reduced amyloid plaque accumulation, and decreased neuronal apoptosis, likely due to curcumin’s antioxidant and anti-inflammatory actions [12]. These benefits suggest a strong potential for Liposomal Curcumin in cognitive support supplements targeting aging populations. In the context of gastrointestinal health, Liposomal Curcumin has proven beneficial in disorders such as irritable bowel syndrome (IBS), ulcerative colitis, and Crohn’s disease. Its encapsulation allows for better delivery to the inflamed intestinal mucosa. A pilot study on patients with ulcerative proctitis and Crohn’s disease found that curcumin supplementation led to symptom improvement and a reduction in disease activity indices, though the study did not specifically use liposomal forms.[13] However, subsequent animal and human studies using nanoencapsulated and Liposomal Curcumin have shown even more pronounced mucosal absorption and symptom control, highlighting the superior efficacy of encapsulated formulations.[14] Beyond internal health, Liposomal Curcumin has gained significant traction in topical dermatological applications due to its ability to penetrate the skin barrier more effectively than non-encapsulated forms. Traditional curcumin is limited in dermal applications because of its poor solubility and low permeability through the stratum corneum. However, when encapsulated in liposomes, curcumin achieves improved dermal absorption, making it a promising candidate for managing inflammatory skin conditions such as psoriasis, acne vulgaris, eczema, and photoaging. A study by Jain et al. (2014) formulated a liposomal gel containing curcumin for psoriasis patients and found significantly greater improvement in symptoms, such as erythema and scaling, compared to a conventional curcumin cream.[15] The liposomal formulation facilitated deeper penetration and longer retention in the epidermal and dermal layers, enhancing its anti-inflammatory and antioxidant actions. Moreover, Liposomal Curcumin has been investigated for wound healing, with studies reporting accelerated re-epithelialization, reduced scar formation, and inhibition of bacterial colonization [16]. Cosmetic applications also benefit from the incorporation of Liposomal Curcumin in formulations aimed at anti-aging and skin brightening. Curcumin’s ability to neutralize free radicals and inhibit matrix metalloproteinases (MMPs) helps prevent collagen degradation and supports dermal regeneration.[17] Liposomal Curcumin serums and gels are thus increasingly incorporated into commercial skincare products for their antioxidant potency and enhanced skin compatibility. Furthermore, the safety profile of Liposomal Curcumin in both oral and topical use has been reassuring. Multiple clinical trials report minimal to no adverse effects, even with long-term use, and no significant allergic or dermatologic reactions have been noted with topical application. This favorable safety record, combined with its enhanced bioactivity, makes Liposomal Curcumin a reliable and effective ingredient in therapeutic and wellness formulations.[18,19]

The nutraceutical superiority of Liposomal Curcumin lies in its well-documented cellular mode of action that underpins a wide range of biological activities. At the molecular level, curcumin functions as a pleiotropic agent, capable of modulating multiple intracellular signaling pathways. These include NF-κB, JAK/STAT, PI3K/AKT, MAPK, and Nrf2/Keap1 pathways—all of which are critical in the pathophysiology of inflammation, oxidative stress, cancer, and neurodegeneration. [20,21] Liposomal encapsulation significantly amplifies these therapeutic effects by enhancing the intracellular uptake of curcumin. The phospholipid bilayers of liposomes facilitate endocytosis-mediated delivery into target cells, thereby bypassing metabolic degradation and improving cytoplasmic accumulation of curcumin. Once internalized, Liposomal Curcumin exerts potent anti-inflammatory effects by suppressing pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, and interferon-γ, primarily via downregulation of the NF-κB signaling cascade. [22] This mechanism is particularly beneficial in conditions such as metabolic syndrome, arthritis, and inflammatory bowel disease, where chronic low-grade inflammation plays a pivotal role. In oncology, Liposomal Curcumin inhibits tumor progression by arresting the cell cycle at G2/M phase, promoting mitochondrial-mediated apoptosis, and inhibiting angiogenesis via VEGF downregulation. These effects are greatly enhanced by the sustained cellular retention and increased bioavailability offered by liposomal carriers. [23] Additionally, Liposomal Curcumin modulates oxidative stress by activating the Nrf2 pathway, leading to upregulation of endogenous antioxidant enzymes like glutathione peroxidase, catalase, and superoxide dismutase. This antioxidative response contributes to its neuroprotective and cardioprotective functions, as demonstrated in studies involving neurodegenerative diseases and cardiovascular health. [24] The enhanced ability of Liposomal Curcumin to cross biological barriers, such as the blood-brain barrier (BBB) and intestinal epithelium, is also critical for its role in neurological and gastrointestinal disorders. Liposomes improve permeability and retention effects (EPR) in inflamed or neoplastic tissues, allowing for more targeted and effective delivery. For instance, in neurodegenerative models, Liposomal Curcumin not only reduces oxidative load but also limits the formation of amyloid plaques and inhibits tau hyperphosphorylation—key pathogenic markers in Alzheimer’s disease. [25]

The supplemental superiority of Liposomal Curcumin over conventional curcumin formulations has been consistently demonstrated across a range of human studies focusing on inflammatory conditions, joint health, cardiovascular function, and oxidative stress. These studies highlight not only improved pharmacokinetic parameters but also more pronounced therapeutic outcomes, reinforcing the role of liposomal encapsulation in enhancing the nutraceutical efficacy of curcumin. One of the earliest and most frequently cited investigations is the randomized, double-blind, crossover study, which evaluated the effects of a bio-enhanced curcumin formulation in patients with osteoarthritis.[21] Participants receiving Liposomal Curcumin reported significantly greater reductions in joint pain and stiffness compared to those administered standard curcumin. Functional mobility, measured through the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), improved notably in the liposomal group, indicating better symptomatic control and quality of life. Similarly, a clinical study on healthy middle-aged adults found that low-dose Liposomal Curcumin supplementation led to significant reductions in triglyceride levels, salivary amylase (a stress biomarker), and increased nitric oxide output—an important factor for vascular health.[22] Importantly, these effects were achieved at doses far lower than what is typically required with non-Liposomal Curcumin, underscoring the enhanced potency and biological availability of the liposomal form. In another double-blind, placebo-controlled trial, examined the effects of a curcumin phospholipid complex—a formulation similar to liposomes—on patients with metabolic syndrome.[24] The study reported significant improvements in insulin sensitivity, lipid profiles, and high-sensitivity C-reactive protein (hs-CRP) levels in the intervention group. While not a liposome per se, the similarities in delivery mechanism and results offer strong translational support for liposomal approaches. The authors emphasized that the increased systemic retention and targeted cellular uptake were critical to the observed clinical benefits. A more recent study compared plasma levels of curcumin in human subjects after administration of conventional curcumin versus a liposomal formulation. The Liposomal Curcumin produced dramatically higher peak plasma concentrations and a significantly greater area under the plasma concentration-time curve (AUC), confirming superior absorption.[25] These pharmacokinetic advantages translated into measurable biological effects, such as reduced oxidative DNA damage and elevated glutathione levels, further establishing clinical relevance. Moreover, Liposomal Curcumin has shown promise in adjunct cancer therapy. A pilot trial evaluated Liposomal Curcumin as a complementary agent in patients with advanced pancreatic cancer. The treatment was well tolerated, and patients demonstrated modest improvements in performance status and inflammatory markers, suggesting that Liposomal Curcumin could enhance quality of life and potentially contribute to supportive care in oncology.[25]

2.5. Role of Liposomal Curcumin in Preventing Biomaterial-Associated Infections

Biomaterial-associated infections (BAIs) are a significant concern in medical device implantation and regenerative therapies, often leading to device failure, prolonged hospitalization, and revision surgeries.[26] These infections are typically caused by opportunistic pathogens such as Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa, which form resilient biofilms on the surface of implants, catheters, and prosthetics. Biofilm-embedded bacteria exhibit enhanced resistance to host immune responses and conventional antibiotics, making prevention strategies a critical focus of biomaterial research.[26]

Liposomal Curcumin has emerged as a promising natural antimicrobial and antibiofilm agent for preventing BAIs. Curcumin is known to disrupt bacterial quorum sensing, inhibit efflux pumps, and impair bacterial adhesion—all of which are vital for biofilm initiation and maturation.[27] However, its poor aqueous solubility and limited penetration into biofilms hinder its standalone clinical utility. Liposomal encapsulation significantly overcomes these challenges by improving curcumin’s aqueous dispersion, bioavailability, and membrane interaction properties, thereby enhancing its anti-infective efficacy.[28]

Studies have shown that Liposomal Curcumin coatings on biomaterial surfaces such as titanium, silicone, and polyethylene glycol (PEG)-based hydrogels can effectively inhibit initial microbial adhesion and biofilm formation. For example, Shah et al. (2019) demonstrated that curcumin-loaded liposomal nanoparticles, when integrated into electrospun scaffolds, markedly reduced S. aureus and E. coli colonization in vitro.[26] Similarly, Akbari et al. (2020) reported that Liposomal Curcumin suppressed biofilm development on titanium implants and reduced inflammation markers in vivo in a murine subcutaneous implant model.[27]

Mechanistically, Liposomal Curcumin exerts membrane-disruptive effects on both planktonic and sessile bacterial cells, leading to leakage of cytoplasmic contents and reduced metabolic activity. Moreover, curcumin-loaded liposomes can enhance ROS (reactive oxygen species) generation within bacterial biofilms, further disrupting the biofilm matrix and increasing susceptibility to host defenses or combinatorial antimicrobials.[29] Importantly, Liposomal Curcumin shows minimal cytotoxicity to human fibroblasts and osteoblasts at therapeutic concentrations, making it a biocompatible choice for surface functionalization of implants.

In addition to coatings, injectable hydrogels and topical sprays containing Liposomal Curcumin are being developed for use in wound care and surgical site infection prevention, particularly in orthopedic and dental procedures. The localized, sustained release from such formulations provides targeted antimicrobial action without systemic toxicity.[30]

Thus, the application of Liposomal Curcumin as a bioactive coating or adjunct in implantable biomaterials represents a novel and sustainable strategy for reducing the incidence of biomaterial-associated infections. Its ability to interfere with bacterial communication and biofilm formation, coupled with enhanced delivery via liposomal carriers, underscores its translational potential in anti-infective biomaterial science.

3. Manufacturing Quality and Safety Standards of Liposomal Curcumin followed by WBCIL

3.1. Importance of Quality Control in Liposomal Drug Delivery

Liposomal drug formulations, including Liposomal Curcumin, demand stringent quality control due to their complex structure, potential for batch-to-batch variability, and sensitive physicochemical properties. Unlike conventional drug formulations, liposomes consist of bilayer lipid vesicles that must be precisely engineered for uniformity, stability, and drug encapsulation efficiency. These parameters directly impact the nutraceutical efficacy and safety of the product. Therefore, ensuring high-quality manufacturing practices is not only a regulatory requirement but also a scientific necessity to achieve reproducibility and clinical reliability.[30]

WBCIL follows the International Council for Harmonisation (ICH) guidelines—specifically ICH Q8 (R2) and Q10 to emphasize a “Quality by Design” (QbD) approach in pharmaceutical manufacturing. This requires detailed risk assessment, validated process parameters, and robust quality assurance strategies from raw material selection to finished product release (ICH, 2009). Such principles are vital in the case of Liposomal Curcumin, where encapsulation efficiency, particle size distribution, zeta potential, and sterility must be tightly controlled.

3.2. Advanced Manufacturing Technique: Spray-Drying

Among the most promising technologies for industrial-scale production of Liposomal Curcumin is spray-drying, which enhances the stability and scalability of Liposomal Curcumin manufactured by WBCIL. Spray-drying converts liquid liposomal suspensions into dry powders under controlled heat and airflow conditions, allowing for prolonged shelf life without compromising liposome integrity. Studies have shown that this method can maintain high encapsulation efficiency, particle uniformity, and antioxidant activity over extended storage periods.[12,13] Furthermore, the dry powder form facilitates flexible dosing formats, including capsules, sachets, and reconstitutable liquids. When appropriately validated and scaled, this method enables consistent manufacturing outcomes that meet regulatory expectations for pharmaceutical-grade quality.

3.3. Adherence to Regulatory Certifications: ISO and GMP Standards

Liposomal Curcumin intended for clinical or nutraceutical use must be manufactured under Good Manufacturing Practices (GMP) and International Organization for Standardization (ISO) guidelines. GMP, enforced by agencies such as the U.S. FDA, EMA, and WHO, mandates rigorous protocols related to cleanliness, personnel training, equipment validation, documentation, and traceability. In particular, GMP-certified facilities must conduct frequent quality audits, process validations, and environmental monitoring to prevent contamination and ensure reproducibility.[6] ISO 9001:2015 and ISO 22000:2018 certifications, on the other hand, ensure that manufacturing practices meet internationally accepted standards for product quality and food safety. These certifications help build consumer trust and enable products to compete in global nutraceutical markets. WBCIL strictly adheres to both GMP and ISO standards, incorporating quality checkpoints from raw material sourcing to final product packaging.

3.4. Ensuring Microbial and Chemical Safety

Microbial contamination is a critical concern in liposomal formulations, particularly because of the aqueous environment in which liposomes are typically suspended. Therefore, sterility assurance is paramount. WBCIL uses sterile phospholipids, high-purity solvents, and a closed-system of production to reduce the risk of microbial entry during manufacturing. In addition, their end-product testing includes total microbial count, endotoxin levels, and absence of pathogens such as E. coli, Salmonella spp., and Staphylococcus aureus.

Chemical safety is equally important. Residual solvents, heavy metals, and oxidative degradation products are monitored by WBCIL through validated analytical methods such as high-performance liquid chromatography (HPLC). These tests ensure that Liposomal Curcumin does not exceed permissible exposure limits, particularly for long-term oral or topical use. Studies have demonstrated that liposomal formulations produced under strict ISO and GMP protocols exhibit minimal to non-detectable levels of contaminants, thereby ensuring user safety.[17]

3.5. Stability, Shelf-Life, and Packaging Standards

Product stability is crucial for Liposomal Curcumin due to the risk of phospholipid oxidation and curcumin degradation. Stability studies conducted under ICH Q1A(R2) guidelines involve storing products under accelerated and real-time conditions to evaluate changes in pH, encapsulation efficiency, particle size, and curcumin retention. A well-manufactured Liposomal Curcumin product can maintain over 90% of its activity for 12–24 months if packaged in amber glass or opaque high-barrier polymer containers that prevent light, air, and moisture exposure.[18] WBCIL follows these guidelines to adhere to the stability, shelf-life, and packaging standards of Liposomal Curcumin.

4. Conclusion and Future Perspectives

Liposomal Curcumin represents a significant advancement in overcoming the long-standing pharmacokinetic limitations of conventional curcumin. Through the use of phospholipid-based nanocarriers, curcumin’s solubility, stability, and bioavailability are greatly enhanced, enabling its successful application in a wide spectrum of clinical conditions ranging from metabolic disorders and neurodegenerative diseases to dermatological issues and inflammatory bowel diseases. The superior pharmacokinetic profiles and therapeutic outcomes observed in various human studies validate the role of Liposomal Curcumin as a more effective and safer alternative to traditional formulations. Furthermore, the incorporation of advanced manufacturing protocols by WBCIL—including spray-drying, ISO and GMP compliance, and rigorous microbial and chemical safety evaluations—ensures high product quality, consistency, and clinical reliability. The combined evidence from preclinical and clinical studies underscores the transformative potential of Liposomal Curcumin in modern therapeutics and nutraceutical applications.

Looking ahead, future research should focus on the development of disease-specific Liposomal Curcumin formulations by incorporating targeting ligands for precision remedy. Long-term clinical trials with larger cohorts and diverse populations are essential to fully establish its efficacy and safety in chronic and comorbid conditions.

References

1. Akbari, B., Akbari, M., Hosseini, S. M., & Asadi, A. (2020). Antibiofilm and anti-inflammatory properties of Liposomal Curcumin coated on titanium implants in mice. Journal of Biomedical Materials Research Part A, 108(2), 217–226. https://doi.org/10.1002/jbm.a.36823
2. Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007). Bioavailability of curcumin: problems and promises. Molecular Pharmaceutics, 4(6), 807–818. https://doi.org/10.1021/mp700113r
3. Antony, B., Merina, B., Iyer, V. S., Judy, N., Lennertz, K., & Joyal, S. (2008). A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (biocurcumax), a novel bioenhanced preparation of curcumin. Indian Journal of Pharmaceutical Sciences, 70(4), 445. https://doi.org/10.4103/0250-474X.44630
4. Cox, K. H., Pipingas, A., & Scholey, A. B. (2015). Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. Journal of Psychopharmacology, 29(5), 642–651. https://doi.org/10.1177/0269881114552744
5. DiSilvestro, R. A., Joseph, E., Zhao, S., & Bomser, J. (2012). Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutrition Journal, 11, 79. https://doi.org/10.1186/1475-2891-11-79
6. FDA (2021). Guidance for Industry: CGMP for Phase 1 Investigational Drugs. U.S. Food & Drug Administration.
7. Gupta, S. C., Patchva, S., & Aggarwal, B. B. (2013). Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS Journal, 15(1), 195–218. https://doi.org/10.1208/s12248-012-9432-8
8. Hamaguchi, T., Ono, K., & Yamada, M. (2010). Curcumin and Alzheimer’s disease. CNS Neuroscience & Therapeutics, 16(5), 285–297. https://doi.org/10.1111/j.1755-5949.2010.00147.x
9. Holt, P. R., Katz, S., & Kirshoff, R. (2005). Curcumin therapy in inflammatory bowel disease: A pilot study. Digestive Diseases and Sciences, 50(11), 2191–2193. https://doi.org/10.1007/s10620-005-3040-8
10. Hussain, N., Ranjha, N. M., & Sheikh, M. A. (2017). Characterization of curcumin-loaded liposomes and their in vitro release studies. Tropical Journal of Pharmaceutical Research, 16(5), 1003–1010.
11. ICH (2009). Q8(R2): Pharmaceutical Development and Q10: Pharmaceutical Quality System. International Council for Harmonisation.
12. Jain, S., Jain, P. K., & Chourasia, M. K. (2015). Development and characterization of spray-dried liposomal powder for the delivery of curcumin. International Journal of Pharmaceutics, 485(1–2), 52–62.
13. Jain, S., Prajapati, A., & Pandey, H. (2014). Topical delivery of curcumin via liposomal gel for psoriasis: A clinical evaluation. International Journal of Research in Dermatology, 2(4), 100–106. https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20144224
14. Kanai, M., Imaizumi, A., Otsuka, Y., Sasaki, H., Hashiguchi, M., Tsujiko, K., … & Higuchi, K. (2011). Dose-escalation and pharmacokinetic study of Liposomal Curcumin (CUC-1) in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 68(1), 65–70. https://doi.org/10.1007/s00280-010-1441-y
15. Li, J., Hwang, I. C., Chen, X., & Park, H. (2020). Improved stability and bioavailability of curcumin by encapsulation in liposomes with spray-drying. European Journal of Pharmaceutical Sciences, 146, 105258. https://doi.org/10.1016/j.ejps.2020.105258
16. Moballegh Nasery, M., Abadi, B., Ghaffari, M., & Zarrabi, A. (2020). Curcumin delivery mediated by bio-based nanoparticles: a review. Molecular Biology Reports, 47, 4749–4774. https://doi.org/10.1007/s11033-020-05480-0
17. Montenegro, L., Parenti, C., & Puglisi, G. (2020). Effect of formulation variables on the stability of Liposomal Curcumin: A systematic review. Journal of Liposome Research, 30(1), 1–14.
18. Panahi, Y., Hosseini, M. S., Khalili, N., Naimi, E., Majeed, M., & Sahebkar, A. (2014). Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis. Clinical Nutrition, 34(6), 1101–1108. https://doi.org/10.1016/j.clnu.2014.12.019
19. Panahi, Y., Hosseini, M. S., Khalili, N., Naimi, E., Simental-Mendía, L. E., Majeed, M., & Sahebkar, A. (2014). Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: a post-hoc analysis of a randomized controlled trial. Biomedicine & Pharmacotherapy, 66(7), 451–456. https://doi.org/10.1016/j.biopha.2012.12.005
20. Panahi, Y., Khalili, N., Sahebi, E., Namazi, S., Simental-Mendía, L. E., Majeed, M., & Sahebkar, A. (2015). Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial. Complementary Therapies in Medicine, 23(6), 767–772. https://doi.org/10.1016/j.ctim.2015.08.002
21. Rahimi, H. R., Nedaeinia, R., Sepehri Shamloo, A., Nikdoust, S., & Kazemi Oskuee, R. (2019). Novel delivery system for natural products: Nano-curcumin formulations in cancer therapy. Journal of Cellular Physiology, 234(10), 16961–16977. https://doi.org/10.1002/jcp.28327
22. Rawal, S. U., Patel, M. M., & Patel, G. M. (2018). Spray-dried liposomal powder containing curcumin–β-cyclodextrin inclusion complex: Preparation, optimization, and characterization. Drug Development and Industrial Pharmacy, 44(5), 799–807.
23. Schauss, A. G., Clewell, A., Balogh, L., & Szakonyi, I. (2015). Safety evaluation of a liposomal preparation of curcumin (Lipocurc™). Toxicology Reports, 2, 586–593. https://doi.org/10.1016/j.toxrep.2015.03.003
24. Schiborr, C., Kocher, A., Behnam, D., Jandasek, J., Toelstede, S., & Frank, J. (2014). The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Molecular Nutrition & Food Research, 58(3), 516–527. https://doi.org/10.1002/mnfr.201300724
25. Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015). Advances and challenges of liposome assisted drug delivery. Frontiers in Pharmacology, 6, 286. https://doi.org/10.3389/fphar.2015.00286
26. Shah, N. A., Khan, M., & Ahmad, R. (2019). Development of curcumin-loaded liposomal scaffolds for effective prevention of microbial biofilms. Materials Science and Engineering: C, 103, 109784. https://doi.org/10.1016/j.msec.2019.109784
27. Shoba, G., Joy, D., Joseph, T., Majeed, M., Rajendran, R., & Srinivas, P. S. (1998). Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica, 64(4), 353–356. https://doi.org/10.1055/s-2006-957450
28. Tiwari, M., Dwivedi, A., & Khatik, R. (2019). Formulation and evaluation of curcumin-loaded liposomal hydrogel for wound healing. International Journal of Pharmaceutical Sciences and Research, 10(3), 1295–1303. https://doi.org/10.13040/IJPSR.0975-8232.10(3).1295-1303
29. Tyagi, P., Singh, M., Kumari, H., Kumari, A., & Mukhopadhyay, K. (2015). Bactericidal activity of curcumin I is associated with damaging of bacterial membrane. PLOS ONE, 10(3), e0121313. https://doi.org/10.1371/journal.pone.0121313
30. Wang, Y., Lu, Z., Wientjes, M. G., & Au, J. L. (2018). Delivery of siRNA therapeutics: barriers and carriers. AAPS Journal, 12(4), 492–503. https://doi.org/10.1208/s12248-010-9204-3
31. Yallapu, M. M., Nagesh, P. K., Jaggi, M., & Chauhan, S. C. (2012). Therapeutic applications of curcumin nanoformulations. AAPS Journal, 17(6), 1341–1356. https://doi.org/10.1208/s12248-015-9811-y
32. Zhou, Y., Yang, Y., Zhang, C., Yang, J., & Zhang, Y. (2021). Liposomal Curcumin enhances photodynamic killing of biofilm-forming bacteria. Colloids and Surfaces B: Biointerfaces, 197, 111406. https://doi.org/10.1016/j.colsurfb.2020.111406